Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

July 3, 2019

CHMP Recommends Tecentriq-Abraxane Combination to Treat Some Triple-negative Breast Cancers in Europe

News

The  Committee for Medicinal Products for Human Use (CHMP),  an arm of the  European Medicines Agency , has recommended the approval of Tecentriq (atezolizumab) in combination with the chemotherapy Abraxane (nab-paclitaxel) as ... Read more

June 21, 2019

Anti-Diarrheal Medicines Improve Tolerability of Nerlynx in Breast Cancer Patients

News

Severe diarrhea is a side effect experienced by more than one-third of women with HER2-positive early-stage breast cancer receiving secondary treatment with Nerlynx (neratinib). But preventive treatment with loperamide ... Read more

May 10, 2019

Kadcyla Approved in US for Some HER2-positive Early Breast Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has extended the use of Genentech‘s Kadcyla (ado-trastuzumab emtansine) as an adjuvant (post-surgery) treatment for some patients with HER2-positive, early-stage breast cancer, the company ... Read more

April 29, 2019April 29, 2019

Clinical Trial Will Test Investigational Therapy Targeting ‘Dormant’ Breast Cancer Cells

News

GlycoMimetics is planning a clinical trial testing its therapy candidate GMI-1359 as a treatment for breast cancer patients whose tumors have spread to the bones, the company announced. GMI-1359 ... Read more

April 24, 2019

Liposomal Irinotecan Shows Promising Phase 1 Results in Heavily Treated Breast Cancer Patients

News

Treatment with a liposomal formulation of irinotecan — meaning the chemotherapy is wrapped up in tiny fatty spheres —was well-tolerated and partially reduced the tumor burden in 35% of ... Read more

March 1, 2019

Pfizer’s Biosimilar Zirabev Approved in E.U. for Advanced Breast, Other Cancers

News

Metastatic breast cancer patients in the European Union will have the possibility of being treated with a biosimilar of Avastin (bevacizumab), following the approval of Pfizer’s Zirabev (bevacizumab) as a more ... Read more

February 8, 2019

FDA to Review Kadcyla for Certain HER2-positive Early-stage Breast Cancer Patients

News

The U.S. Food and Drug Administration is reviewing Kadcyla (trastuzumab emtansine) as a post-surgery treatment for early-stage breast cancer patients whose tumors produce the HER2 factor, Roche announced. The supplemental biologics license ... Read more

December 14, 2018

Couple Share $1.8 Million to Test More Precise Image-guided Breast Radiation Therapy

News

A new strategy for delivering a higher dose of radiotherapy with increased precision to breast tumors — while sparing healthy tissue — has been awarded more than $1.8 million ... Read more

November 30, 2018

2 Trials, Now Enrolling, Aimed at Improving Breast Cancer Prevention, Diagnosis, and Treatment

News

The University of Hawaiʻi Cancer Center is enrolling participants in two clinical trials to test new ways of preventing and diagnosing breast cancer, as well as improving current treatments. “These trials are ... Read more

November 26, 2018

Tecentriq-Chemo Combo Under FDA Review as First-line Therapy for PD-L1-positive, Metastatic Triple-negative Breast Cancer

News

The U.S. Food and Drug Administration (FDA) is reviewing Genentech’s request for Tecentriq (atezolizumab) to be approved, in combination with the chemotherapy Abraxane (nab-paclitaxel), as a first-line treatment for certain triple-negative breast cancer patients. The supplemental Biologics ... Read more

Pin It on Pinterest